Literature DB >> 28656360

Erratum to: Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.

Ali Afshar-Oromieh1,2, Tim Holland-Letz3, Frederik L Giesel4, Clemens Kratochwil4, Walter Mier4, Sabine Haufe4, Nils Debus4, Matthias Eder5, Michael Eisenhut6, Martin Schäfer6, Oliver Neels6, Markus Hohenfellner7, Klaus Kopka6, Hans-Ulrich Kauczor8, Jürgen Debus9, Uwe Haberkorn4,5.   

Abstract

Entities:  

Year:  2017        PMID： 28656360      PMCID： PMC6828271          DOI： 10.1007/s00259-017-3763-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  3 in total

1.  Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series.

Authors:  Berardino De Bari; Rosario Mazzola; Dario Aiello; Sergio Fersino; Fabiana Gregucci; Pierpaolo Alongi; Maurizio Nicodemo; Stefano Cavalleri; Matteo Salgarello; Filippo Alongi
Journal:  Radiol Med       Date:  2018-04-23       Impact factor: 3.469

2.  68Ga-PSMA and 11C-Choline comparison using a tri-modality PET/CT-MRI (3.0 T) system with a dedicated shuttle.

Authors:  Omar Alonso; Gerardo Dos Santos; Margarita García Fontes; Henia Balter; Henry Engler
Journal:  Eur J Hybrid Imaging       Date:  2018-05-07

3.  Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?

Authors:  Emre Demirci; Levent Kabasakal; Onur E Şahin; Elife Akgün; Mehmet Hamza Gültekin; Tünkut Doğanca; Mustafa B Tuna; Can Öbek; Mert Kiliç; Tarik Esen; Ali R Kural
Journal:  Nucl Med Commun       Date:  2019-01       Impact factor: 1.690
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.